The historical rank and industry rank for Novartis India's FCF Margin % or its related term are showing as below:
BOM:500672'
s FCF Margin % Range Over the Past 10 Years
Min: -46.26 Med: 10.95 Max: 33.95
Current: 13.09
During the past 13 years, the highest FCF Margin % of Novartis India was 33.95%. The lowest was -46.26%. And the median was 10.95%.
BOM:500672's FCF Margin % is ranked better than 77.3% of 956
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs BOM:500672: 13.09
Novartis India FCF Margin % Related Terms
Novartis India FCF Margin % Historical Data
* Premium members only.
The historical data trend for Novartis India's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis India FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis India's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Novartis India's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis India (BOM:500672) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Novartis India and its competitors. According to the industry distribution chart, Novartis India ranks #217 out of 956 companies in the Drug Manufacturers industry, placing it in the top 22.7%.
Is Novartis India's FCF Margin % too high?
Novartis India's current FCF Margin % is 0.00%. Based on the distribution chart, Novartis India ranks #217 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novartis India has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #217 out of 956 companies for FCF Margin %. This places Novartis India in the top 23% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Novartis India and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis India's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (BOM:500672) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹928.24, compared to a current price of ₹1,440.95 — trading 55.2% above its estimated fair value. The current FCF Margin % is 0.00%. Novartis India's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Novartis India (BOM:500672), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis India (BOM:500672) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis India stock appears to be overvalued.
The current stock price of ₹1,440.95 is trading 55.2% above its estimated GF Value™ of ₹928.24.
GuruFocus considers Novartis India to be Significantly Overvalued.
Key valuation signals for BOM:500672:
FCF Margin %: 0.00%
GF Value™: ₹928.24 vs. price of ₹1,440.95 (55.2% above fair value)
No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
59GF Score
Get the complete analysis for BOM:500672
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500672 has been successfully added to your 
